Nations Financial Group Inc. IA ADV Purchases 2,813 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Nations Financial Group Inc. IA ADV lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,447 shares of the biopharmaceutical company’s stock after buying an additional 2,813 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Gilead Sciences were worth $708,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. TFB Advisors LLC grew its holdings in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $788,000 after acquiring an additional 116 shares in the last quarter. Sumitomo Life Insurance Co. boosted its stake in shares of Gilead Sciences by 0.7% during the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 117 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 3.9% during the third quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 123 shares during the period. Roberts Wealth Advisors LLC raised its stake in Gilead Sciences by 1.9% in the third quarter. Roberts Wealth Advisors LLC now owns 7,035 shares of the biopharmaceutical company’s stock worth $599,000 after buying an additional 130 shares in the last quarter. Finally, Wagner Wealth Management LLC boosted its position in Gilead Sciences by 1.7% during the 3rd quarter. Wagner Wealth Management LLC now owns 8,026 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.8 %

Gilead Sciences stock opened at $92.63 on Thursday. The firm has a market cap of $115.32 billion, a PE ratio of 1,029.22, a P/E/G ratio of 2.91 and a beta of 0.17. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The stock’s 50 day simple moving average is $85.95 and its two-hundred day simple moving average is $75.57. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.39 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. Gilead Sciences’s payout ratio is 3,422.22%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. The Goldman Sachs Group upped their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $91.50.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.